Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. (linkinghub.elsevier.com)

Authors: Klein KR … Meskimen ER Journal: The Lancet Published: 2026-09-30 DOI: https://doi.org/10.1016/S0140-6736(26)01865-9